Haemonetics Corp. (HAE) financials: revenue, earnings and cash flow
Fiscal 2017–2026 + TTM · from SEC filings · data as of November 13, 2026
Summary
Haemonetics’s revenue went from $886M in fiscal 2017 to $1.3B in fiscal 2026, growth of about 4.7% a year.
Net income in fiscal 2026 was $97M, a net margin of 7.3%; the best year in this period was 2025 with $168M.
Over the twelve months to September 26, 2026, revenue was $1.4B and net income $104M.
Free cash flow was $260M in fiscal 2026 and positive in 10 of the 10 years shown.
The diluted share count fell 8% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.3B | $1.4B | $1.3B | $1.2B | $993M | $870M | $988M | $968M | $904M | $886M |
| Gross profit | $824M | $788M | $749M | $692M | $615M | $506M | $398M | $485M | $418M | $412M | $378M |
| Operating income | $177M | $157M | $222M | $165M | $156M | $81M | $90M | $103M | $84M | $56M | -$19M |
| Net income | $104M | $97M | $168M | $118M | $115M | $43M | $79M | $77M | $55M | $46M | -$26M |
| EPS (diluted) | $2.26 | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 | $1.48 | $1.04 | $0.85 | $-0.51 |
| R&D | $62M | $60M | $63M | $54M | $50M | $47M | $33M | $31M | $36M | $39M | $38M |
| Revenue growth | — | −2.0% | +4.0% | +12.0% | +17.7% | +14.1% | −11.9% | +2.2% | +7.0% | +2.0% | −2.5% |
Cash flow
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $345M | $293M | $182M | $182M | $273M | $172M | $109M | $158M | $159M | $220M | $160M |
| Capital spending | -$47M | -$33M | -$39M | -$38M | -$191M | -$97M | -$37M | -$49M | -$119M | -$75M | -$76M |
| Free cash flow | $298M | $260M | $142M | $144M | $82M | $76M | $72M | $109M | $40M | $146M | $84M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $100M | $175M | $225M | $0 | $75M | $0 | $0 | $175M | $160M | $100M | $0 |
| Stock-based pay | $36M | $34M | $30M | $28M | $26M | $24M | $26M | $20M | $17M | $13M | $9M |
Balance sheet
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $245M | $307M | $179M | $284M | $259M | $192M | $137M | $169M | $180M | $140M |
| Debt | — | $1.3B | $1.3B | $874M | $829M | $836M | $778M | $442M | $350M | $254M | $316M |
| Equity | — | $796M | $821M | $960M | $818M | $749M | $732M | $587M | $668M | $752M | $740M |
| Total assets | — | $2.4B | $2.5B | $2.2B | $1.9B | $1.9B | $1.8B | $1.3B | $1.3B | $1.2B | $1.2B |
| Shares (diluted) | 46M | 47M | 51M | 51M | 51M | 51M | 51M | 52M | 53M | 54M | 52M |
Margins and returns
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 59.6% | 59.0% | 55.0% | 52.8% | 52.6% | 50.9% | 45.7% | 49.0% | 43.1% | 45.6% | 42.7% |
| Operating margin | 12.8% | 11.8% | 16.3% | 12.6% | 13.4% | 8.1% | 10.3% | 10.5% | 8.6% | 6.2% | -2.2% |
| Net margin | 7.5% | 7.3% | 12.3% | 9.0% | 9.9% | 4.4% | 9.1% | 7.7% | 5.7% | 5.0% | -3.0% |
| FCF margin | 21.6% | 19.5% | 10.5% | 11.0% | 7.0% | 7.6% | 8.2% | 11.1% | 4.2% | 16.1% | 9.4% |
| ROIC | — | 5.7% | 8.2% | 7.0% | 7.7% | 3.5% | 4.7% | 8.8% | 6.1% | 4.3% | -1.8% |
| ROE | — | 12.2% | 20.4% | 12.2% | 14.1% | 5.8% | 10.9% | 13.0% | 8.2% | 6.1% | -3.5% |
Frequently asked questions
What is Haemonetics’s annual revenue?
$1.3B in fiscal 2026 and $1.4B over the twelve months to September 26, 2026.
How much profit does Haemonetics make?
Net income was $97M in fiscal 2026 (net margin 7.3%).
Is Haemonetics’s revenue growing?
No: revenue fell 2.0% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.